Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18817843 | 0.92 | DGAT1 (0.43) | DGAT1TDP1MAOAMAOB | |
| SCHEMBL8970993 | 0.87 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL3031027 | 0.84 | DGAT1 (0.52) | DGAT1CA2CA12CA14TDP1 | |
| SCHEMBL27960447 | 0.84 | DGAT1 (0.52) | DGAT1CA2CA12CA14TDP1 | |
| SCHEMBL28390923 | 0.82 | DGAT1 (0.50) | DGAT1CA2CA12CA14TDP1 | |
| SCHEMBL27801427 | 0.82 | DGAT1 (0.50) | DGAT1CA2CA12CA14TDP1 | |
| SCHEMBL5027322 | 0.82 | DGAT1 (0.46) | DGAT1TDP1MAOAMAOB | |
| SCHEMBL28721112 | 0.82 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL609386 | 0.82 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL1066622 | 0.82 | DGAT1 (0.39) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105085428-A | Heteroaromatic derivative and application thereof to medicament | GUANGDONG HEC PHARMACEUTICAL | 2015-11-25 | — | — | CN | disclosed |
| CN-100434420-C | Compounds that block dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO (JP) | 2008-11-19 | — | — | CN | disclosed |
| EP-1754705-A2 | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | Genentech, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1063982-B1 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | GENENTECH INC (US) | 2007-02-14 | — | — | EP | disclosed |
| CN-1745063-A | Compound inhibiting dipeptidyl peptidase iv | SANWA KAGAKU KENKYUSHO CO (JP) | 2006-03-08 | — | — | CN | disclosed |
| US-20050148588-A1 | LFA-1 antagonist compounds | GENENTECH, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6872735-B2 | LFA-1 antagonist compounds | GENENTECH, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-6667318-B2 | Antiinflammatory agents; autoimmune disease | GENENTECH, INC. | 2003-12-23 | — | — | US | disclosed |
| US-20020119994-A1 | LFA-1 Antagonist compounds | GENENTECH, INC | 2002-08-29 | — | — | US | disclosed |
| CN-1202893-A | Novel isoxazoline and isoxazole fibrinogen receptor antagonists | DU PONT MERCK PHARMA (US) | 1998-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119994-A1 | LFA-1 Antagonist compounds | ICAM1, VCAM1, CD58 | DGAT1 3980/4885CA2 3393/4885CA12 3589/4885 |
| US-20050148588-A1 | LFA-1 antagonist compounds | CD58, VCAM1, ICAM1 | DGAT1 3514/4885CA2 3748/4885CA12 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.